TNF and psoriasis: Methotrexate [7] and tumor necrosis factor‐alpha (TNF‐α) inhibitors [8, 9, 10] represent well‐recognized agents associated with reduced cardiovascular risk in patients with psoriasis, PsA, and rheumatoid arthritis.